Cannatrol Brings Breakthrough Postharvest Cannabis Tech to Europe in Partnership With Paralab Green
11.7.2024 15:03:00 EEST | Business Wire | Press release
Cannatrol, the creators of the only total dry, cure and store system for the cannabis industry, announced today an exclusive partnership with Paralab Green, Europe’s premier distributor of cannabis processing solutions, establishing distribution of the company’s patented Vaportrol® Technology throughout Europe.
“This partnership truly represents the best of cannabis processing,” said Jane Sandelman, CEO and Co-Founder of Cannatrol. “Paralab Green has established relationships within the European cannabis industry and has a unique understanding of the rapidly growing market. We look forward to opening international access to Cannatrol’s science-backed technology that will benefit cultivators—and ultimately consumers.”
Paralab Green supplies over 70% of licensed production facilities throughout the European Union, offering a range of instrumentation for the cannabis industry, from production to quality control.
“The European market continues to lead the way in Good Manufacturing Practices (GMP) compliance, and this partnership with Cannatrol is a pivotal addition that enhances our portfolio at Paralab Green,” said Rui Soares, CEO of Paralab Green. “The Cannatrol team brings invaluable scientific expertise to optimize and simplify the drying and curing process. This collaboration reinforces our commitment to excellence, raising industry standards and delivering exceptional value to our customers.”
Cannatrol systems ensure consistent water activity and vapor pressure, delivering elevated product quality, increased yields, GMP regulatory compliance and bottom-line improvements. Cannatrol’s patented postharvest technology is proven to increase curing efficiency, and delivers on average 16% higher terpene retention when compared to traditional drying and curing methods, according to independent testing by The Cannabis Research Coalition.
In addition to Europe, Paralab Green operates in Israel, North Africa and Latin America—opening the door for operators in those regions to access Cannatrol technology.
To learn more about Cannatrol’s Vaportrol® Technology, visit cannatrols.com.
About Cannatrol
Cannatrol supports commercial cannabis cultivation by streamlining and tightly controlling the critical drying, curing processes as well as postharvest storage. With patented Vaportrol® Technology, the system controls water loss by regulating the vapor pressure and ensures the correct final water activity, critical for terpene preservation, maximized potency, increased yield and premium quality. Cannatrol’s environmental control solution ensures consistent results for every climate and geography, taking the guesswork and risk out of seasonal humidity and temperature swings. Learn more at cannatrols.com.
About Paralab Green
Paralab Green, a division of Paralab with 32 years of industry leadership, specializes in providing innovative equipment solutions tailored for the cannabis industry. With a background in serving the pharmaceutical, biotechnology, energy, and chemical sectors, Paralab Green brings extensive expertise to cannabis cultivation, extraction, and production. Operating from offices in Portugal and Spain, we are the trusted solution provider for the majority of licensed producers in Europe. Paralab Green combines technical prowess with exceptional customer support to drive innovation and set new standards in the cannabis sector. Learn more at paralab-green.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711844879/en/
Contacts
Danna Tabachnik
Grasslands: A Journalism-Minded Agency
danna@mygrasslands.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom